Analysis: Regulatory pathway for biosimilars is still unclear

11/2/2010 | Reuters

Although FDA officials have started discussing the creation of a regulatory pathway for approving biosimilars, the agency has not set a deadline for the implementation of such a system, and it could take at least five years for such drugs to reach the market, experts said. "People will be frustrated. It's not going to be a clear pathway for everything," said Ian Spatz, a policy consultant in Washington, D.C., and a former executive at Merck & Co.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ